TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23828709

Group type: EXPERIMENTAL
Intervention: Modified cesarean hysterectomy by peritoneum lateral approach
Number of subjects: 8

Group type: COMPARATOR
Intervention: Conventional cesarean hysterectomy
Number of subjects: 8
Study: 21967156

Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21298859

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg
Number of subjects: 17802

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 17802
Study: 17116021

Group type: EXPERIMENTAL
Intervention: RWJ-333369 (100-750 mg)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: RWJ-333369 (750 mg)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: RWJ-333369 (750 mg) under fed conditions
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 15592291

Group type: EXPERIMENTAL
Intervention: Intravenous nitroglycerin
Number of subjects: 59

Group type: COMPARATOR
Intervention: Subcutaneous terbutaline
Number of subjects: 59
Study: 11451268

Group type: EXPERIMENTAL
Intervention: Physiologic pacing (AAI or DDD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ventricular-based pacing
Number of subjects: 0
Study: 9209786

Group type: EXPERIMENTAL
Intervention: Clarithromycin (CAM) 400 mg/day, orally
Number of subjects: 49

Group type: COMPARATOR
Intervention: No treatment (non-CAM)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Clarithromycin (CAM)
Number of subjects: 49
Study: 7957544

Group type: EXPERIMENTAL
Intervention: Umespirone 20 mg
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Umespirone 80 mg
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Buspirone 30 mg
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 3624110

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (250 mg single oral dose)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Ampicillin (2 g single oral dose and 500 mg four times per day for five days)
Number of subjects: 84
Study: 31909431

Group type: COMPARATOR
Intervention: Off-OAC group (3149 patients)
Number of subjects: 4512

Group type: EXPERIMENTAL
Intervention: On-OAC group (1363 patients)
Number of subjects: 4512

Group type: COMPARATOR
Intervention: OAC discontinuation
Number of subjects: 4512

Group type: EXPERIMENTAL
Intervention: Previous history of ischaemic stroke/transient ischaemic attack/systemic embolism
Number of subjects: 4512

Group type: EXPERIMENTAL
Intervention: Diabetes mellitus
Number of subjects: 4512
Study: 31172934

Group type: EXPERIMENTAL
Intervention: Visual-spatial training
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional neurorehabilitation (Control)
Number of subjects: 30
Study: 28872081

Group type: EXPERIMENTAL
Intervention: Iso+SBP group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Iso group
Number of subjects: 0
Study: 26685401

Group type: EXPERIMENTAL
Intervention: Preserving the great auricular nerve
Number of subjects: 81

Group type: COMPARATOR
Intervention: No preserving the great auricular nerve
Number of subjects: 81
Study: 23328881

Group type: EXPERIMENTAL
Intervention: Community-wide intervention including education on smoking hazards and ETS exposure, conducted by trained professionals.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (villages not receiving the intervention).
Number of subjects: 0
Study: 21782948

Group type: EXPERIMENTAL
Intervention: Sub-antimicrobial-dose doxycycline (SDD) for 3 months
Number of subjects: 45

Group type: COMPARATOR
Intervention: Antimicrobial-dose doxycycline (ADD) for 2 weeks
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 19812587

Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine gluconate
Number of subjects: 48

Group type: COMPARATOR
Intervention: 10% povidone-iodine
Number of subjects: 48
Study: 16469161

Group type: EXPERIMENTAL
Intervention: 25 g glucose
Number of subjects: 0

Group type: COMPARATOR
Intervention: saccharin
Number of subjects: 0
Study: 15131558

Group type: EXPERIMENTAL
Intervention: Oral rosiglitazone for 6 months
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Oral rosiglitazone
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 11296803

Group type: EXPERIMENTAL
Intervention: Standardized exercises (SE) and continuous passive motion (CPM)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Standardized exercises (SE) and slider board (SB) therapy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standardized exercises (SE) alone
Number of subjects: 120
Study: 9310811

Group type: EXPERIMENTAL
Intervention: Apnoea tests without CO2 augmentation (group A)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Apnoea tests with CO2 augmentation (group B)
Number of subjects: 55
Study: 8317029

Group type: EXPERIMENTAL
Intervention: Buprenorphine (priming dose i.m. at wound closure, sublingual buprenorphine every eight hours)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Morphine (priming dose i.m. at wound closure, sublingual placebo every eight hours)
Number of subjects: 3
Study: 2873106

Group type: EXPERIMENTAL
Intervention: Extempore combination of salbutamol syrup plus 30‐mg oxatomide tablets
Number of subjects: 40

Group type: COMPARATOR
Intervention: 30‐mg oxatomide tablets alone
Number of subjects: 40
Study: 31511891

Group type: EXPERIMENTAL
Intervention: EC‐IC bypass surgery in rHEMI+ patients
Number of subjects: 195

Group type: COMPARATOR
Intervention: Medical treatment in rHEMI+ patients
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: EC‐IC bypass surgery in rHEMI- patients
Number of subjects: 195

Group type: COMPARATOR
Intervention: Medical treatment in rHEMI- patients
Number of subjects: 195

Group type: COMPARATOR
Intervention: Nonsurgical treatment for rHEMI+ vs rHEMI- patients
Number of subjects: 195
Study: 29447309

Group type: EXPERIMENTAL
Intervention: Customized zirconia abutments (AC)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Customized titanium abutments (MC)
Number of subjects: 28
Study: 26954991

Group type: EXPERIMENTAL
Intervention: Aerobic exercise alone
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Aerobic exercise and cognitive training combined
Number of subjects: 14
Study: 26549374

Group type: EXPERIMENTAL
Intervention: Self-expanding stents
Number of subjects: 69

Group type: COMPARATOR
Intervention: Balloon-expandable stents
Number of subjects: 69
Study: 23701262

Group type: EXPERIMENTAL
Intervention: GSK256073 5 mg BID
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: GSK256073 10 mg QD
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: GSK256073 25 mg BID
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: GSK256073 50 mg QD
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 20496734

Group type: EXPERIMENTAL
Intervention: Catgut embedding
Number of subjects: 86

Group type: COMPARATOR
Intervention: Electroacupuncture
Number of subjects: 86
Study: 17454835

Group type: EXPERIMENTAL
Intervention: Preoperative carbohydrate drink
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (no carbohydrate drink)
Number of subjects: 18
Study: 15026831

Group type: EXPERIMENTAL
Intervention: CFS patients
Number of subjects: 10

Group type: COMPARATOR
Intervention: Healthy control subjects (CON)
Number of subjects: 10
Study: 11174230

Group type: EXPERIMENTAL
Intervention: Sublingual hyoscyamine sulfate (0.125 mg) with ketorolac tromethamine (30 mg IV)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo with ketorolac tromethamine (30 mg IV)
Number of subjects: 43
Study: 9670686

Group type: EXPERIMENTAL
Intervention: Laferon therapy as part of complex treatment schemes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 8149520

Group type: EXPERIMENTAL
Intervention: TPA
Number of subjects: 1473

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1473

Group type: EXPERIMENTAL
Intervention: Early invasive strategy
Number of subjects: 1473

Group type: COMPARATOR
Intervention: Early conservative strategy
Number of subjects: 1473
Study: 2458219

Group type: EXPERIMENTAL
Intervention: Product A (Procan‐SR)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Product B (Pronestyl‐SR)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both products
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Product A to Product B switch
Number of subjects: 10
Study: 31437865

Group type: EXPERIMENTAL
Intervention: Tegoprazan 50 mg
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Tegoprazan 100 mg
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Tegoprazan 200 mg
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Tegoprazan 400 mg
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Tegoprazan 100 mg (multiple doses)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Tegoprazan 200 mg (multiple doses)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Esomeprazole 40 mg (control)
Number of subjects: 56
Study: 29570740

Group type: EXPERIMENTAL
Intervention: Waist-worn accelerometer
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Wrist-worn accelerometer
Number of subjects: 141

Group type: COMPARATOR
Intervention: Automated DT algorithm
Number of subjects: 141
Study: 26498603

Group type: EXPERIMENTAL
Intervention: 6-h magnesium sulfate therapy (4 g loading dose followed by 1 gm/h infusion for 6 h)
Number of subjects: 119

Group type: COMPARATOR
Intervention: 24-h conventional magnesium sulfate therapy (4 g loading dose followed by 1 gm/h infusion for 24 h)
Number of subjects: 119
Study: 25379838

Group type: EXPERIMENTAL
Intervention: 5-point Balanced Equal-Interval
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: 5-point Positive-Packed
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: 5-point Positive-Centered Equal-Interval
Number of subjects: 216
Study: 21766483

Group type: EXPERIMENTAL
Intervention: Supervised aerobic exercise (12 weeks)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 122
Study: 19926370

Group type: EXPERIMENTAL
Intervention: Sirolimus, mycophenolate mofetil, and prednisone
Number of subjects: 127

Group type: COMPARATOR
Intervention: Cyclosporine, mycophenolate mofetil, and prednisone
Number of subjects: 127
Study: 17400979

Group type: EXPERIMENTAL
Intervention: Modified Broncho-Cath R-DLT
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard Broncho-Cath R-DLT
Number of subjects: 80
Study: 15448985

Group type: EXPERIMENTAL
Intervention: Alendronate (5-20 mg/day, with over 95% receiving 5 or 10 mg/day)
Number of subjects: 0
Study: 12375486

Group type: EXPERIMENTAL
Intervention: Group counseling
Number of subjects: 174

Group type: COMPARATOR
Intervention: In-class enrichment program
Number of subjects: 174
Study: 10476344

Group type: EXPERIMENTAL
Intervention: Testosterone and 5 alpha‐dihydrotestosterone
Number of subjects: 46
Study: 8760846

Group type: EXPERIMENTAL
Intervention: Tip‐Edge bracket system
Number of subjects: 12

Group type: COMPARATOR
Intervention: A‐Company straight wire bracket system
Number of subjects: 12
Study: 1761174

Group type: EXPERIMENTAL
Intervention: Local application of metronidazole (500 mg vaginal suppository) before hysterectomy
Number of subjects: 242

Group type: COMPARATOR
Intervention: Control group (no metronidazole prophylaxis)
Number of subjects: 242
Study: 7043104

Group type: EXPERIMENTAL
Intervention: Weight-reduction treatment program with diet instruction and weekly meetings with a dietitian for 16 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group received only diet instruction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups made successful changes in behavior resulting in seemingly permanent reductions in weight
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Evaluation through triceps skinfold measurements, parents' questionnaire, and structured interview
Number of subjects: 0
Study: 30762156

Group type: EXPERIMENTAL
Intervention: Bringing in the Bystander‐High School Curriculum (BITB‐HSC)
Number of subjects: 2403

Group type: COMPARATOR
Intervention: Control condition (no BITB‐HSC)
Number of subjects: 2403
Study: 27979041

Group type: EXPERIMENTAL
Intervention: Standard care (pharmacologic or electrical cardioversion)
Number of subjects: 437

Group type: COMPARATOR
Intervention: Wait-and-see approach (rate control medication until spontaneous conversion, with possible cardioversion within 48 hours)
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: Standard care
Number of subjects: 437

Group type: COMPARATOR
Intervention: Wait-and-see approach
Number of subjects: 437
Study: 25945079

Group type: EXPERIMENTAL
Intervention: Acute magnesium supplementation (300 mg/d for 1 week)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Chronic magnesium supplementation (300 mg/d for 4 weeks)
Number of subjects: 13
Study: 23329006

Group type: EXPERIMENTAL
Intervention: Immediate adenoidectomy
Number of subjects: 111

Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 111
Study: 22109781

Group type: EXPERIMENTAL
Intervention: Integrative neuromuscular training (INT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 40
Study: 19122548

Group type: EXPERIMENTAL
Intervention: Butorphanol (n = 96): intravenous loading dose of 10 microg kg(‐1) butorphanol followed by infusion of 2 microg kg(‐1) h(‐1) butorphanol combined with intravenous PCA set at a bolus of 0.02 mg kg(‐1) morphine
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Butorphanol (n = 96)
Number of subjects: 186
Study: 17329511

Group type: EXPERIMENTAL
Intervention: Induction of labor at 41 weeks
Number of subjects: 508

Group type: COMPARATOR
Intervention: Expectant management (antenatal fetal surveillance every third day)
Number of subjects: 508
Study: 15352914

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg on-demand
Number of subjects: 774

Group type: COMPARATOR
Intervention: Lansoprazole 15 mg continuous
Number of subjects: 774
Study: 11434941

Group type: EXPERIMENTAL
Intervention: Intralipid 10% (1.5 ml/min)
Number of subjects: 8

Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 8
Study: 9887454

Group type: EXPERIMENTAL
Intervention: 5-year therapy
Number of subjects: 60
Study: 8556965

Group type: EXPERIMENTAL
Intervention: Amantadine 200 mg p.o. daily
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Amantadine 200 mg p.o. bid
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 2307923

Group type: EXPERIMENTAL
Intervention: Interns after 1 year of clinical experience
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experienced clinicians
Number of subjects: 0
Study: 7351166

Group type: EXPERIMENTAL
Intervention: Aurokeratinate (Auro-Detoxin) administered intramuscularly at slowly rising doses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aurokeratinate (Auro-Detoxin) at 25 mg gold twice weekly
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aurokeratinate (Auro-Detoxin) at 65 mg gold once a month
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aurokeratinate (Auro-Detoxin) at 50 mg gold every 14 days as maintenance dose
Number of subjects: 0
Study: 30664604

Group type: EXPERIMENTAL
Intervention: COPD patients undergoing TSA
Number of subjects: 931
Study: 27815324

Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 48

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 48
Study: 26426576

Group type: COMPARATOR
Intervention: Thoracic Epidural Analgesia (TEA)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Lateral-to-Medial Continuous Transversus Abdominis Plane Block (LM-TAP)
Number of subjects: 50
Study: 22750663

Group type: EXPERIMENTAL
Intervention: Telemedicine group (paramedic teams supported by telemedicine)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (physician staffed EMS teams)
Number of subjects: 16
Study: 20573925

Group type: EXPERIMENTAL
Intervention: Early-TIPS group (polytetrafluoroethylene‐covered stent within 72 hours after randomization)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Pharmacotherapy-EBL group (continuation of vasoactive-drug therapy, propranolol or nadolol, long-term endoscopic band ligation)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Early-TIPS group
Number of subjects: 63

Group type: COMPARATOR
Intervention: Pharmacotherapy-EBL group
Number of subjects: 63
Study: 18405061

Group type: EXPERIMENTAL
Intervention: Phasic REM sleep
Number of subjects: 11

Group type: COMPARATOR
Intervention: Tonic REM sleep
Number of subjects: 11
Study: 16807023

Group type: COMPARATOR
Intervention: Salmeterol 50 microg and Fluticasone propionate 500 microg Diskus, one inhalation twice daily for 12 weeks
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Salmeterol 50 microg and Fluticasone propionate 500 microg Diskus plus 20 mg Enoxaparin administered subcutaneously once daily for 12 weeks
Number of subjects: 46
Study: 12756427

Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10997957

Group type: EXPERIMENTAL
Intervention: ANDRO‐6 (300 mg androstenedione, 150 mg DHEA, 750 mg Tribulus terrestris, 625 mg Chrysin, 300 mg Indole‐3‐carbinol, 540 mg Saw palmetto)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8792252

Group type: EXPERIMENTAL
Intervention: Dual-energy x-ray absorptiometry
Number of subjects: 45
Study: 1735264

Group type: EXPERIMENTAL
Intervention: Verapamil, 120 mg three times daily
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 6694008

Group type: EXPERIMENTAL
Intervention: Low-pressure spray irrigation of corn fields with partially treated wastewater
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control population with no direct exposure to wastewater
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Workers cleaning spray nozzles
Number of subjects: 0
Study: 30862817

Group type: EXPERIMENTAL
Intervention: Phonological language tasks
Number of subjects: 49

Group type: COMPARATOR
Intervention: Semantic language tasks
Number of subjects: 49
Study: 30552284

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 51

Group type: COMPARATOR
Intervention: Prednisone/prednisolone
Number of subjects: 51
Study: 26933301

Group type: EXPERIMENTAL
Intervention: Driver Sleepiness Score (DSS)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Epworth Sleepiness Scale (ESS)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: DSS and ESS administered together
Number of subjects: 73
Study: 24562803

Group type: EXPERIMENTAL
Intervention: SPIM risk score
Number of subjects: 12109
Study: 22434095

Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum 299v
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 21183965

Group type: EXPERIMENTAL
Intervention: Laparoscopic living donor nephrectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open approach nephrectomy
Number of subjects: 0
Study: 17660173

Group type: EXPERIMENTAL
Intervention: TIVA with propofol and remifentanil
Number of subjects: 60

Group type: COMPARATOR
Intervention: Desflurane and nitrous oxide
Number of subjects: 60
Study: 17216221

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) 2 g/day for 3 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 30
Study: 14656737

Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Regular human insulin
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 10
Study: 11034267

Group type: EXPERIMENTAL
Intervention: DigiTAb
Number of subjects: 16

Group type: COMPARATOR
Intervention: Digibind
Number of subjects: 16
Study: 9339678

Group type: EXPERIMENTAL
Intervention: Immediate treatment (carbamazepine, phenytoin, phenobarbital, or sodium valproate)
Number of subjects: 419

Group type: COMPARATOR
Intervention: Delayed treatment (treatment only after another seizure)
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Immediate treatment
Number of subjects: 419

Group type: COMPARATOR
Intervention: Delayed treatment
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Immediate treatment and delayed treatment
Number of subjects: 419
Study: 8449431

Group type: EXPERIMENTAL
Intervention: 0.5 mg PGE2
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: 1.5 mg PGE2
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: 2.5 mg PGE2
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Oxytocin requirement
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Overall labor characteristics
Number of subjects: 110
Study: 3535135

Group type: EXPERIMENTAL
Intervention: Continuous postoperative peritoneal lavage
Number of subjects: 79

Group type: COMPARATOR
Intervention: No continuous postoperative peritoneal lavage (Control)
Number of subjects: 79
Study: 31852711

Group type: EXPERIMENTAL
Intervention: 3-month dual antiplatelet therapy (DAPT)
Number of subjects: 2446

Group type: COMPARATOR
Intervention: 12-month dual antiplatelet therapy (DAPT)
Number of subjects: 2446
Study: 28238742

Group type: COMPARATOR
Intervention: Vehicle/emollient control
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pimecrolimus
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Betamethasone dipropionate
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Steroids (including clobetasol)
Number of subjects: 30
Study: 26549156

Group type: EXPERIMENTAL
Intervention: Behavioral interventions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pharmacological treatments
Number of subjects: 0
Study: 23751727

Group type: EXPERIMENTAL
Intervention: Compression Stockings (CS)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (non-CS)
Number of subjects: 11
Study: 22229005

Group type: EXPERIMENTAL
Intervention: Application of Vidrion-R (SS White) glass ionomer sealant
Number of subjects: 51

Group type: COMPARATOR
Intervention: No clinical intervention (Control)
Number of subjects: 51
Study: 19934290

Group type: COMPARATOR
Intervention: KRAS-mutated tumors
Number of subjects: 508

Group type: COMPARATOR
Intervention: KRAS-wild-type tumors
Number of subjects: 508
Study: 18063539

Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 0

Group type: COMPARATOR
Intervention: Granisetron
Number of subjects: 0
Study: 14724047

Group type: EXPERIMENTAL
Intervention: Enforced smoking abstinence
Number of subjects: 12

Group type: COMPARATOR
Intervention: Free smoking
Number of subjects: 12